Artificial intelligence (AI) cerebrovascular software developer RapidAI expanded its market reach and grew its client base to 60 countries in 2020. It also raised $25 million in funding to support this expansion.
The company increased its scope from stroke to aneurysm, in part by acquiring EndoVantage, thus paving the way for further expansion into the vascular imaging market. It processed more than 1 million stroke imaging scans, a 1,900% increase over 2017, and partnered with therapy products firm Penumbra in an effort to expand into the pulmonary embolism market.
The U.S. Food and Drug Administration cleared the company's Rapid Aspects software for neuroimaging analysis on noncontrast CT, as well as its Rapid LVO software for detecting large-vessel occlusions, it said.
